ISS III: The Evolving Treatment Landscape in Advanced Ovarian Cancer: The Integral Role of PARP Inhibitors

MTCC: 701

This symposium is supported by GSK.

Moderators:
Bradley J. Monk, MD, Phoenix – Biltmore Cancer Center, Phoenix, AZ
Amit M. Oza, MD, Princess Margaret Cancer Centre, Toronto, Canada

Speakers:
Bradley J. Monk, MD, Phoenix – Biltmore Cancer Center, Phoenix, AZ
Kathleen N. Moore, MD, The University of Oklahoma, Oklahoma City, OK
Mansoor R. Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Amit M. Oza, MD, Princess Margaret Cancer Centre, Toronto, Canada

Description:
Scientific satellite symposium to explore the treatment landscape in advanced ovarian cancer as it continues to evolve. The focus will be on the role of PARP inhibitors in the advanced ovarian cancer patient’s treatment journey in the first-line maintenance setting. The relevance of the latest Phase III data to clinical practice will be discussed through case study examples. A panel discussion will enable the audience to interact with the faculty.

Top